OHSU hosts Sen. Ron Wyden, Sen. Jeff Merkley and Rep. Suzanne Bonamici in a press conference calling attention to the devastating impacts of reducing NIH indirect cost funding for OHSU and science in general. Peter Barr-Gillespie, Ph.D., says, ““If it goes through, it will cripple our ability to do biomedical research at OHSU.” Marc Freeman, Ph.D., says, “Everything we do depends on this robust NIH support. It’s as if you took your car to mechanic, and then someone said you can’t use 40% of your tools. It’s not a recipe for success.”

OHSU hosts Sen. Ron Wyden, Sen. Jeff Merkley and Rep. Suzanne Bonamici in a press conference calling attention to the devastating impacts of reducing NIH indirect cost funding for OHSU and science in general. Peter Barr-Gillespie, Ph.D., says, ““If it goes through, it will cripple our ability to do biomedical research at OHSU.” Marc Freeman, Ph.D., says, “Everything we do depends on this robust NIH support. It’s as if you took your car to mechanic, and then someone said you can’t use 40% of your tools. It’s not a recipe for success.”

OHSU hosts Sen. Ron Wyden, Sen. Jeff Merkley and Rep. Suzanne Bonamici in a press conference calling attention to the devastating impacts of reducing NIH indirect cost funding for OHSU and science in general. Peter Barr-Gillespie, Ph.D., says, ““If it goes through, it will cripple our ability to do biomedical research at OHSU.” Marc Freeman, Ph.D., says, “Everything we do depends on this robust NIH support. It’s as if you took your car to mechanic, and then someone said you can’t use 40% of your tools. It’s not a recipe for success.”

Interim President Steve Stadum, J.D., discusses challenges—including federal actions on research funding and patient care—and opportunities—including the proposed integration with Legacy—on the TV station’s long-form interview show, KGW Straight Talk. “OHSU has the resources, the capital to invest in Legacy's facilities, which is one of the commitments we've made, because Legacy's facilities are under-utilized. One of the goals of this merger, or acquisition, if you will, is to improve access. That means to reduce wait times. Wait times in the Portland area are unacceptably high. The status quo is definitely not working.”

OHSU — Oregon's largest research institution and the state's largest recipient of NIH grant money — would be hit the hardest.

Oregon’s U.S. Senators Jeff Merkley and Ron Wyden join an effort led by Washington State’s U.S. Senator Patty Murray in expressing serious alarm over the Trump Administration’s threats to cut the National Institutes of Health’s federal funding to research universities and institutions across American and in Oregon, including OHSU; the senators joined the entire Senate democratic caucus in signing a letter to Robert F. Kennedy, Jr., Secretary, U.S. Department of Health & Human Services.

Medscape reports on findings presented by Ava Mandelbaum, B.A., at the Society for Maternal-Fetal Medicine 2025 Annual Pregnancy Meeting, that conclude an interval of less than 1 year or at least 5 years between pregnancies was linked to an increased risk for adverse pregnancy outcomes in patients who had a history of preeclampsia.

The Dana Farber Cancer Institute and the German Cancer Research Centre have joined the international Alliance for Cancer Early Detection (ACED) initiative, led by the OHSU Knight Cancer Institute, Cancer Research UK, University of Manchester, University College London, and the University of Cambridge. Incoming alliance chair Rebecca Fitzgerald said, “The next phase of the expanding ACED network is an exciting opportunity for collaborations in early cancer detection.”

Ben Burwitz, Ph.D., and his research team develop the first transgenic nonhuman primate model for studying hepatitis B virus. The breakthrough could lead to the development of new treatments for the disease, which affects about 250 million people globally and results in nearly 1 million deaths annually. Burwitz says, “We’ve seen success with treatments for hepatitis C that wipe out the virus, and that’s the goal here. Developing a drug that’s effective, easy to distribute and affordable for global populations is critical.”

In a TCTMD story about a new drug to treat transthyretin amyloid cardiomyopathy, Ahmad Masri, M.D., says, “We went from a condition that was 100% fatal, untreatable, and no approved medications to now having a couple. This is a very early real-world study done right around the time of approval and we’re already seeing there are signals where mortality looks better than what we have expected.”